AROHIF-2 is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase I program in Renal Cell Carcinoma. According to Globaldata, it is involved in 1 clinical trial, which was completed. GlobalData uses proprietary data and analytics to provide a complete picture of AROHIF-2’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for AROHIF-2 is expected to reach an annual total of $177 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ARO-HIF2 is under development for the treatment of clear cell renal cell carcinoma (ccRCC). It is administered through subcutaneous and intravenous routes. The drug candidate is an RNAi therapeutic which acts by targeting hypoxia-inducible factor 2alpha (HIF-2alpha). It is developed based on extra-hepatic dynamic polyconjugate (DPC) delivery technology.
Arrowhead Pharmaceuticals Overview
Arrowhead Pharmaceuticals (Arrowhead), formerly Arrowhead Research, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new therapies. The company has operations in California and Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
The company reported revenues of (US Dollars) US$243.2 million for the fiscal year ended September 2022 (FY2022), an increase of 75.9% over FY2021. The operating loss of the company was US$178.5 million in FY2022, compared to an operating loss of US$149 million in FY2021. The net loss of the company was US$176.1 million in FY2022, compared to a net loss of US$140.9 million in FY2021. The company reported revenues of US$62.6 million for the first quarter ended December 2022, an increase of 98.1% over the previous quarter.
For a complete picture of AROHIF-2’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.